128 related articles for article (PubMed ID: 37244566)
21. Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Aβ deposits in hippocampus via distinct cellular mechanisms.
Hartlage-Rübsamen M; Morawski M; Waniek A; Jäger C; Zeitschel U; Koch B; Cynis H; Schilling S; Schliebs R; Demuth HU; Rossner S
Acta Neuropathol; 2011 Jun; 121(6):705-19. PubMed ID: 21301857
[TBL] [Abstract][Full Text] [Related]
22. Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer's disease patients.
Bridel C; Hoffmann T; Meyer A; Durieux S; Koel-Simmelink MA; Orth M; Scheltens P; Lues I; Teunissen CE
Alzheimers Res Ther; 2017 Jun; 9(1):38. PubMed ID: 28587659
[TBL] [Abstract][Full Text] [Related]
23. Discovery of Potent Human Glutaminyl Cyclase Inhibitors as Anti-Alzheimer's Agents Based on Rational Design.
Hoang VH; Tran PT; Cui M; Ngo VT; Ann J; Park J; Lee J; Choi K; Cho H; Kim H; Ha HJ; Hong HS; Choi S; Kim YH; Lee J
J Med Chem; 2017 Mar; 60(6):2573-2590. PubMed ID: 28234463
[TBL] [Abstract][Full Text] [Related]
24. Glutaminyl cyclase in human cortex: correlation with (pGlu)-amyloid-β load and cognitive decline in Alzheimer's disease.
Morawski M; Schilling S; Kreuzberger M; Waniek A; Jäger C; Koch B; Cynis H; Kehlen A; Arendt T; Hartlage-Rübsamen M; Demuth HU; Roßner S
J Alzheimers Dis; 2014; 39(2):385-400. PubMed ID: 24164736
[TBL] [Abstract][Full Text] [Related]
25. Potent human glutaminyl cyclase inhibitors as potential anti-Alzheimer's agents: Structure-activity relationship study of Arg-mimetic region.
Ngo VTH; Hoang VH; Tran PT; Ann J; Cui M; Park G; Choi S; Lee J; Kim H; Ha HJ; Choi K; Kim YH; Lee J
Bioorg Med Chem; 2018 Mar; 26(5):1035-1049. PubMed ID: 29398442
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis and anti-AD effects of dual inhibitor targeting glutaminyl cyclase/GSK-3β.
Xie Y; Chen C; Lin S; Yu X; Ye S; Chen X; Ouyang N; Xiong W; Li C; Xu C; Song G; Wu H
Eur J Med Chem; 2023 Feb; 248():115089. PubMed ID: 36638710
[TBL] [Abstract][Full Text] [Related]
27. Identification of Glutaminyl Cyclase Genes Involved in Pyroglutamate Modification of Fungal Lignocellulolytic Enzymes.
Wu VW; Dana CM; Iavarone AT; Clark DS; Glass NL
mBio; 2017 Jan; 8(1):. PubMed ID: 28096492
[TBL] [Abstract][Full Text] [Related]
28. Disturbed Ca2+ homeostasis increases glutaminyl cyclase expression; connecting two early pathogenic events in Alzheimer's disease in vitro.
De Kimpe L; Bennis A; Zwart R; van Haastert ES; Hoozemans JJ; Scheper W
PLoS One; 2012; 7(9):e44674. PubMed ID: 22970285
[TBL] [Abstract][Full Text] [Related]
29. Hypothesis: glutaminyl cyclase inhibitors decrease risks of Alzheimer's disease and related dementias.
Hennekens CH; Bensadon BA; Zivin R; Gaziano JM
Expert Rev Neurother; 2015; 15(11):1245-8. PubMed ID: 26450764
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and Evaluation of Diphenyl Conjugated Imidazole Derivatives as Potential Glutaminyl Cyclase Inhibitors for Treatment of Alzheimer's Disease.
Li M; Dong Y; Yu X; Li Y; Zou Y; Zheng Y; He Z; Liu Z; Quan J; Bu X; Wu H
J Med Chem; 2017 Aug; 60(15):6664-6677. PubMed ID: 28700245
[TBL] [Abstract][Full Text] [Related]
31. Distinct glutaminyl cyclase expression in Edinger-Westphal nucleus, locus coeruleus and nucleus basalis Meynert contributes to pGlu-Abeta pathology in Alzheimer's disease.
Morawski M; Hartlage-Rübsamen M; Jäger C; Waniek A; Schilling S; Schwab C; McGeer PL; Arendt T; Demuth HU; Rossner S
Acta Neuropathol; 2010 Aug; 120(2):195-207. PubMed ID: 20383514
[TBL] [Abstract][Full Text] [Related]
32. Discovery of potent indazole-based human glutaminyl cyclase (QC) inhibitors as Anti-Alzheimer's disease agents.
Van Manh N; Hoang VH; Ngo VTH; Kang S; Jeong JJ; Ha HJ; Kim H; Kim YH; Ann J; Lee J
Eur J Med Chem; 2022 Dec; 244():114837. PubMed ID: 36265279
[TBL] [Abstract][Full Text] [Related]
33. Amyloidogenic processing of amyloid precursor protein: evidence of a pivotal role of glutaminyl cyclase in generation of pyroglutamate-modified amyloid-beta.
Cynis H; Scheel E; Saido TC; Schilling S; Demuth HU
Biochemistry; 2008 Jul; 47(28):7405-13. PubMed ID: 18570439
[TBL] [Abstract][Full Text] [Related]
34. Inhibitory effect of flavonoids on human glutaminyl cyclase.
Li M; Dong Y; Yu X; Zou Y; Zheng Y; Bu X; Quan J; He Z; Wu H
Bioorg Med Chem; 2016 May; 24(10):2280-6. PubMed ID: 27061673
[TBL] [Abstract][Full Text] [Related]
35. Glutaminyl cyclase inhibitor exhibits anti-inflammatory effects in both AD and LPS-induced inflammatory model mice.
Wang X; Wang L; Yu X; Li Y; Liu Z; Zou Y; Zheng Y; He Z; Wu H
Int Immunopharmacol; 2019 Oct; 75():105770. PubMed ID: 31377588
[TBL] [Abstract][Full Text] [Related]
36. Piperidine-4-carboxamide as a new scaffold for designing secretory glutaminyl cyclase inhibitors.
Dileep KV; Sakai N; Ihara K; Kato-Murayama M; Nakata A; Ito A; Sivaraman DM; Shin JW; Yoshida M; Shirouzu M; Zhang KYJ
Int J Biol Macromol; 2021 Feb; 170():415-423. PubMed ID: 33373636
[TBL] [Abstract][Full Text] [Related]
37. Increased glutaminyl cyclase expression in peripheral blood of Alzheimer's disease patients.
Valenti MT; Bolognin S; Zanatta C; Donatelli L; Innamorati G; Pampanin M; Zanusso G; Zatta P; Dalle Carbonare L
J Alzheimers Dis; 2013; 34(1):263-71. PubMed ID: 23207485
[TBL] [Abstract][Full Text] [Related]
38. Association of multiple nucleotide variations in the pituitary glutaminyl cyclase gene (QPCT) with low radial BMD in adult women.
Ezura Y; Kajita M; Ishida R; Yoshida S; Yoshida H; Suzuki T; Hosoi T; Inoue S; Shiraki M; Orimo H; Emi M
J Bone Miner Res; 2004 Aug; 19(8):1296-301. PubMed ID: 15231017
[TBL] [Abstract][Full Text] [Related]
39. A Unique Carboxylic-Acid Hydrogen-Bond Network (CAHBN) Confers Glutaminyl Cyclase Activity on M28 Family Enzymes.
Huang KF; Huang JS; Wu ML; Hsieh WL; Hsu KC; Hsu HL; Ko TP; Wang AH
J Mol Biol; 2021 Jun; 433(13):166960. PubMed ID: 33774034
[TBL] [Abstract][Full Text] [Related]
40. Glutaminyl Cyclase Inhibitor PQ912 Improves Cognition in Mouse Models of Alzheimer's Disease-Studies on Relation to Effective Target Occupancy.
Hoffmann T; Meyer A; Heiser U; Kurat S; Böhme L; Kleinschmidt M; Bühring KU; Hutter-Paier B; Farcher M; Demuth HU; Lues I; Schilling S
J Pharmacol Exp Ther; 2017 Jul; 362(1):119-130. PubMed ID: 28446518
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
